| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A triumph for physiology driving drug discovery: the potential impact of dipeptidyl peptidase-IV inhibitors in type 2 diabetes
|
|
|
2007
|
9 |
2 |
p. 151-152
|
artikel
|
| 2 |
Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug
|
Idris, Iskandar
|
|
2007
|
9 |
2 |
p. 153-165
|
artikel
|
| 3 |
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetes
|
Brazg, R.
|
|
2007
|
9 |
2 |
p. 186-193
|
artikel
|
| 4 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
|
Nauck, M. A.
|
|
2007
|
9 |
2 |
p. 194-205
|
artikel
|
| 5 |
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
|
Rosenstock, J.
|
|
2007
|
9 |
2 |
p. 175-185
|
artikel
|
| 6 |
News and Views
|
Holt, Richard I. G.
|
|
2007
|
9 |
2 |
p. 206-208
|
artikel
|
| 7 |
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study *
|
Garber, A. J.
|
|
2007
|
9 |
2 |
p. 166-174
|
artikel
|
Tijdschrift beschrijving